The burden of hepatitis C virus infection in children: estimated direct medical costs over a 10-year period.
about
Chronic Hepatitis C Infection in Children: Current Treatment and New TherapiesBurden of pediatric hepatitis CDiagnosis, management, and treatment of hepatitis C: an updateThe Role of Direct-acting Antivirals in the Treatment of Children with Chronic Hepatitis C.Ophthalmologic complications in children with chronic hepatitis C treated with pegylated interferonHepatitis C in the pediatric population: transmission, natural history, treatment and liver transplantation.Hepatitis C virus infection during pregnancy and the newborn period--are they opportunities for treatment?Guidelines for the prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children: recommendations from the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of theEconomic burden of hepatitis C-associated diseases in the United States.The burden of hepatitis C in Europe from the patients' perspective: a survey in 5 countriesThe combination of ribavirin and peginterferon is superior to peginterferon and placebo for children and adolescents with chronic hepatitis C.Peginterferon with or without ribavirin has minimal effect on quality of life, behavioral/emotional, and cognitive outcomes in childrenAssociation between interleukin-18 gene promoter (- 607C/A and - 137G/C) polymorphisms and chronic hepatitis C virus infections: A meta-analysis.Hepatitis C Virus (HCV) Vertical Transmission in 12-Month-Old Infants Born to HCV-Infected Women and Assessment of Maternal Risk Factors.Performance of the AST-to-platelet ratio index as a noninvasive marker of fibrosis in pediatric patients with chronic viral hepatitisRecruitment and retention strategies in a clinical trial for children with chronic hepatitis C infectionSingle Clinical Practice's Report of Testing Initiation, Antibody Clearance, and Transmission of Hepatitis C Virus (HCV) in Infants of Chronically HCV-Infected Mothers.CD4+ and CD8+ T Cell Activation in Children with Hepatitis C.Seroprevalence and Correlates of Hepatitis C Virus Infection in Secondary School Children in Enugu, Nigeria.Vertical transmission of hepatitis C virus: a tale of multiple outcomesManaging pediatric hepatitis C: current and emerging treatment options.Chronic hepatitis C virus infection in children and adolescents: Epidemiology, natural history, and assessment of the safety and efficacy of combination therapy.Treatment of chronic viral hepatitis C in children and adolescents: UK experience.Hepatitis B and C.Interferon-α plus ribavirin yields 98 % sustained virologic response in children aged 1-5 years with iatrogenic chronic hepatitis C.Genetic variation in interleukin 28B with respect to vertical transmission of hepatitis C virus and spontaneous clearance in HCV-infected children.Current treatment options and response rates in children with chronic hepatitis C.Quality of Life in Adolescents with Hepatitis C Treated with Sofosbuvir and Ribavirin.The burden of untreated hepatitis C virus infection: a US patients' perspective.Hepatitis C virus infection in children in the era of direct-acting antiviral.Clinical utility of ledipasvir/sofosbuvir in the treatment of adolescents and children with hepatitis C
P2860
Q26781770-5AE313DB-BA96-47E4-AA59-3F895F8A56C3Q27025476-B39EE293-427B-49D8-AB00-FB88FA3B258DQ29619682-AB0015C7-99D0-41FC-8C0F-A738ED5ED189Q33621649-5EF5EA5D-1BE5-40C1-B2FC-332CA14F54CFQ34023159-0B99312D-9BFC-4675-9EBB-BEB530C7B787Q34093840-767E15CD-53FC-484F-8B40-A2450FB97C37Q34169767-2C00AFBE-FDAA-4DA1-827C-788A7CA47629Q34212799-D7407042-7474-4F8F-A3D5-2616B37A7B94Q34253963-8187B0A8-3103-4DC4-B9F9-62AA7E506BECQ34550098-6270B713-BEE8-4D05-9439-5D2369A9C22FQ34588247-F5E664B5-0D0B-4F64-A8A6-AD3CDDD0B3B9Q34861058-5639030C-9D01-4520-A7E8-C5D8EFEE630CQ35645186-91E3F1E4-1DB3-48AA-96A1-565DCDC52241Q35837823-8ED0F861-EEF8-4C00-9AFC-15D71D0E614BQ35859323-5D9641EF-E9AB-4685-8840-FBC37B07ADBCQ36518161-410ECD60-165A-4FEA-95A1-A49FB3AAA456Q36681311-103A4436-35C7-4A27-B652-2109619CE903Q36803044-FDEDFDCF-EBE1-44FB-9D54-F888FD2D2A5DQ37045880-95C24D61-6E4D-4C91-AFB3-8818BFD94681Q37297300-795E980A-A267-4E72-A285-D55382E71579Q37316248-D88C37A5-5A63-4E29-BBE8-2E4B7EB3450CQ37561618-2C058C68-C27A-4DA7-90B7-A4476F7DAA02Q38184887-7280DD4A-0394-4694-A36E-08DEEEC4FE86Q39305112-584C8F83-57A6-4234-839E-30F7A8C27D7BQ40961029-85C9A334-92D4-462D-8004-C48CB2EE57A1Q43035295-E2F07519-9E57-4227-BE9A-49B807A4E41EQ43046510-88064B79-F741-4D59-A6FC-187F31BC2E03Q45074467-EA7AC478-82B1-4F72-A407-4BDC7914A599Q45357120-C8EB894A-DF1E-4F01-B703-C9D6E8BF5D45Q55381219-14748592-32D2-4A21-972F-153FC6F58CC2Q56395991-2F7A8259-A2C3-4CE2-A8DB-6F606B3CFF34
P2860
The burden of hepatitis C virus infection in children: estimated direct medical costs over a 10-year period.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh-hant
name
The burden of hepatitis C viru ...... l costs over a 10-year period.
@en
The burden of hepatitis C viru ...... l costs over a 10-year period.
@nl
type
label
The burden of hepatitis C viru ...... l costs over a 10-year period.
@en
The burden of hepatitis C viru ...... l costs over a 10-year period.
@nl
prefLabel
The burden of hepatitis C viru ...... l costs over a 10-year period.
@en
The burden of hepatitis C viru ...... l costs over a 10-year period.
@nl
P2093
P1476
The burden of hepatitis C viru ...... l costs over a 10-year period.
@en
P2093
John McHutchison
Teresa L Kauf
William Grant
P304
P356
10.1016/J.JPEDS.2005.10.031
P407
P577
2006-03-01T00:00:00Z